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Background: The two oppositely imprinted and expressed genes, DLK1 and MEG3, are located in the same gene
cluster at 14q32. Previous studies in bladder cancer have suggested that tumor suppressor genes are located in this
region, but these have not been identified.
Results: We observed that both DLK1 and MEG3 are frequently silenced in urothelial cancer tissues and cell lines.
The concomitant downregulation of the two genes is difficult to explain by known mechanisms for inactivating
imprinted genes, namely deletion of active alleles or epitype switching. Indeed, quantitative PCR revealed more
frequent copy number gains than losses in the gene cluster that were, moreover, consistent within each sample,
excluding gene losses as the cause of downregulation. Instead, we observed distinctive epigenetic alterations at
the three regions controlling DLK1 and MEG3 expression, namely the DLK1 promoter; the intergenic (IG) and MEG3
differentially methylated regions (DMRs). Bisulfite sequencing and pyrosequencing revealed novel patterns of DNA
methylation in tumor cells, which were distinct from that of either paternal allele. Furthermore, chromatin
immunoprecipitation demonstrated loss of active and gain of repressive histone modifications at all regulatory
sequences.
Conclusions: Our data support the idea that the main cause of the prevalent downregulation of DLK1 and MEG3
in urothelial carcinoma is epigenetic silencing across the 14q32 imprinted gene cluster, resulting in the unusual
concomitant inactivation of oppositely expressed and imprinted genes.
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The differential expression of alleles inherited from
mother or father at genomic imprinted genes is achieved
by epigenetic mechanisms, particularly by differential
methylation at regulatory regions designated as differen-
tially methylated regions (DMRs). Imprinted genes re-
gulate growth and other physiological functions during
embryonic development, but also in adult tissues. Since
several maternally imprinted genes limit growth, they
possess tumor-suppressive potential and tend to become
inactivated in different types of human cancer [1]. Their
inactivation in cancers is brought about by deletion of* Correspondence: wolfgang.schulz@hhu.de
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unless otherwise stated.the active allele or by a change of the epigenetic state of
the active allele to that of the inactive one, that is, epitype
switching. Importantly, either mechanism results in a
homogeneous epigenetic state that corresponds to that of
the normally inactive paternal allele. A well-studied ex-
ample is the imprinted tumor suppressor gene CDKN1C,
which is inactivated alternatively by genetic or epigenetic
mechanisms in several human cancers, including urothe-
lial carcinoma [2,3].
In several cancers, a cluster of imprinted genes at
14q32.2, the DLK1-MEG3 cluster, is affected by allelic
losses or epigenetic changes [4-7]. This cluster compri-
ses several protein-coding and nonprotein-coding genes
(ncRNAs), including antisense RNAs (asRNAs), small nu-
cleolar RNAs (snoRNAs or C/D RNAs) and microRNAs
(miRNAs) (Figure 1). The paternally expressed genes in-
clude the three protein-coding genes Delta-like 1 (DLK1),td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic presentation of the DLK1-DIO3 imprinting cluster at chromosome 14q32.2. The DLK1-DIO3 cluster contains three
paternally expressed protein coding genes (light gray arrows) and multiple maternally expressed noncoding RNAs (dark gray arrows). The
respective inactive gene copies are not shown. It is debated whether BEGAIN and DIO3-AS (white) are biallelically expressed. Arrowheads indicate
the direction of transcription. Imprinting is regulated by differentially methylated regions (DMR), the IG DMR and the MEG3 DMR, methylated at
the paternal allele (black circle) and unmethylated at the maternal allele (white circle). The relative localizations of selected microRNAs and the
C/D RNA unit are indicated by dashed arrowheads.
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transposon-like Gene 1 (RTL1 or PEG11) [8]. The mater-
nally expressed genes Maternally Expressed Gene 3
(MEG3), Maternally Expressed Gene 8 (MEG8) and RTL1
antisense (RTL1-AS) [9,10] encode long noncoding RNAs.
Gene expression in the cluster is controlled by differen-
tially methylated regions (DMR) located 11 kb upstream
of MEG3 (intergenic differentially methylated region, IG
DMR) and 1.3 kb upstream of the MEG3 transcription
start site (MEG3 DMR) [11]. DNA methylation in the
DLK1 promoter is also relevant for its expression. The IG
DMR, which is methylated on the paternal allele and
unmethylated on the maternal allele, serves as the initial
imprinting control region (ICR) for the entire cluster
during early development [12], whereas in adult tissues
the MEG3 DMR usually represents the dominant regula-
tory region [13]. The expression of DLK1 and MEG3 is
commonly reciprocal, possibly as a consequence of regula-
tory effects of the MEG3 RNA [12].
Loss of imprinting in the 14q32 region due to epimuta-
tions at the IG DMR or microdeletions has been impli-
cated in a range of diseases including UPD14mat/pat
(uniparental disomy 14) and various cancers [4-7]. In renal
and hepatic cancers and certain leukemia, a loss of DLK1
expression is associated with changes in DNA methylation
at this gene and its control regions [5,14-16]. MEG3 has
been reported to act as a tumor suppressor in a broader
range of cancers [1,17-19]. Both DLK1 and MEG3 exert
various functions relevant for cancer development andprogression, including regulation of growth factors and
Notch signaling by DLK1, and regulation of TP53, pRB1
and NOTCH activity by MEG3 [20-22].
Urothelial carcinoma is the most common cancer of
the urinary bladder. It can be categorized into two sub-
types, namely papillary tumors and the more malignant
invasive carcinomas, which are characterized by pro-
nounced chromosomal instability [23,24]. In particular,
more than 30% of invasive urothelial cancers, especially
high stage cases, have been reported to contain losses at
14q32 [25-28]. It is therefore thought that the region
harbors a tumor suppressor gene antagonizing cancer
progression. Given their known functions and the findings
in other cancers, DLK1 and MEG3 are good tumor-
suppressor candidates. Indeed, MEG3 has recently been
reported to become downregulated in the majority of
urothelial carcinomas and to exert tumor-suppressive
functions [29]. However, the mechanism of its downregu-
lation has not been investigated, yet.
Unexpectedly, we found that expression of both DLK1
and MEG3 was strongly diminished in urothelial carcin-
oma tissues and cell lines. This finding raises a conun-
drum as it is difficult to envision how either allelic loss or
epitype switching could lead to the concomitant down-
regulation of these two imprinted and normally inversely
expressed genes, which are located less than 100 kb apart.
Indeed, upon closer investigation, we found that inactiva-
tion of the two genes is associated with the establishment
of a novel epigenetic state in the region, which is distinct
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copy number changes in most urothelial carcinoma tissues
and cell lines. This epigenetic state involves a characteris-
tic DNA methylation pattern and a strong shift towards
repressive histone modifications across three major regu-
latory regions in this imprinted gene cluster. This me-
chanism could provide a means to silence both genes
despite their normal opposite regulation.
Results
DLK1 and MEG3 expression are concomitantly diminished
in urothelial cancer
Initially, we quantified DLK1 and MEG3 mRNA by qPCR
in urothelial cancer tissues (n = 30) and cell lines com-
pared to benign bladder tissue samples (n = 11) and
primary cultured normal urothelial cells. Normal kidney
tissue and the hepatoma cell line HepG2 were used as
additional positive controls. DLK1 mRNA was sig-
nificantly reduced in urothelial cancer tissues compared
to normal bladder tissue (Figure 2A) and was low or
undetectable in all investigated urothelial carcinoma cell
lines but remained detectable, albeit at lower levels, in
cultured normal urothelial cells (Figure 2B). MEG3 was
robustly expressed in benign bladder tissues and more
moderately in normal urothelial cells, but was significantlyFigure 2 DLK1 and MEG3 expression in urothelial tissues and cells. Q
expression relative to the reference gene TBP. (A, C) Boxplot representation
(BN) versus 30 cancerous (BT) urothelial tissue samples. (B, D) DLK1 and ME
carcinoma cell lines (papillary: BC61, BFTC905, J82, RT4, RT112, SW1710; invasiv
HepG2 hepatoma cells. Statistical comparisons between benign bladder and
with SPSS 21.reduced in urothelial cancer tissues and totally absent in
urothelial cancer cell lines (Figure 2C and D). In accord
with previous reports [5,30] HepG2 expressed only DLK1.
Downregulation of DLK1 and MEG3 occurs irrespective of
frequent copy number gains and losses at 14q32.2
We measured copy number changes at DLK1 and both
DMRs in the chromosomal region 14q32.2 by qPCR in
bladder cancer tissues and cell lines to assess whether
gene deletions were responsible for the decreased expres-
sion of the two genes in urothelial carcinoma (Figure 3).
In benign bladder tissue samples (BN) measured copy
numbers varied between 1.7 and 2.2, as normalized to
normal diploid leukocytes set at two copies. Of 23
urothelial carcinoma samples (BT), 10 cases displayed
increased copy numbers and 5 cases had decreased copy
numbers, whereas 8 tumors showed copy numbers in
the normal range (1.7 to 2.2). Importantly, gene copy
number changes affected all three analyzed loci to the
same extent within each sample.
Similarly, gene copy number changes affected all ana-
lyzed genes to the same extent in urothelial cancer cell
lines (UC). Primary urothelial cell cultures (UP) were mea-
sured as diploid, as expected. Seven cell lines displayed
elevated copy numbers between 2.5 and 3.5 across theuantitative reverse polymerase chain reaction (RT-PCR) analysis of gene
s of DLK1 (P = 0.004) and MEG3 expression (P = 0.01) in 11 benign
G3 expression in cultured normal urothelial cells (UP) and urothelial
e: 5637, 639v, 647v, HT1376, SD, T24, VmCub1, Umuc3) in comparison to
tumor bladder tissue expression were made by the Mann-Whitney U Test
Figure 3 Gene copy number analysis of the 14q32 imprinting cluster. Gene copy numbers analysis by qPCR of the DLK1 promoter (blue
squares), the IG DMR (green rhombi) and the MEG3 DMR (red triangles) in leukocytes, benign (BN) and cancerous (BT) bladder tissues, urothelial
cancer cell lines and normal urothelial cells (UP). Copy numbers were normalized to those in leukocytes set as 2 and to GAPDH as a reference
gene. The asterisks indicate samples analyzed for DNA methylation by bisulfite sequencing. All other samples were analyzed only by pyrosequencing.
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lines. In accord with our results the predicted modal copy
numbers are 3 for Umuc3 and 639v [31]. Decreased copy
numbers were measured in two urothelial cancer cell lines
and in HepG2. The decreased copy number measured for
SW1710 is compatible with its hypotetraploid karyotype
with one or two chromosomes number 14 per cell. Six
cancer cell lines retained normal copy numbers. As in
tumor tissues, all copy numbers were very similar, in the
range of the technical variation (< ±10%), for the three
loci.
Thus, whereas copy numbers of the 14q region were
variously increased or decreased in urothelial carcinoma
tissues and cell lines, MEG3 and DLK1 expression was
reduced in almost all urothelial cancer tissues and cell
lines, irrespective of copy numbers [see Additional file 1:
Table S2].
Urothelial cancers display distinctive DNA methylation
changes in the chromosome 14q32.2 imprinted gene
cluster
To investigate whether MEG3 and DLK1 downregula-
tion was associated with changes in DNA methylation,
we analyzed the three relevant CpG-rich regulatory re-
gions, the DLK1 promoter, the IG DMR, and the MEG3
DMR, by bisulfite sequencing in selected urothelial can-
cer tissue and cell line samples (marked by asterisks inFigure 3). The analysis included two urothelial cancer cells
lines representing extremes in differentiation and invasive-
ness (highly invasive SW1710 versus well-differentiated
BC61 cells) and HepG2 as a control for a DLK1 expressing
cell line.
The DLK1 promoter was partly methylated in benign
kidney and bladder tissues as well as in leukocytes (Figure 4,
left). While the methylation of individual alleles was het-
erogeneous, there was a tendency for the more distal CpGs
(1-4) to be methylated and the central CpGs (5-10) to be
unmethylated. In contrast, in urothelial cancer cell lines
(SW1710, BC61) and urothelial cancer tissues (BT152 and
BT186), methylation at the promoter assumed a homoge-
neous pattern with methylated CpGs at the center of the
sequence flanked by unmethylated CpG sites at its margins
(Figure 4). A tendency towards this pattern was also seen
in HepG2 (Figure 4).
Bisulfite sequencing analysis of the IG DMR in normal
kidney and bladder tissues, leukocytes and cultured nor-
mal urothelial cells revealed the mixture of nearly fully
methylated and nearly unmethylated alleles that is typi-
cal of imprinted DMRs (Figure 4). In HepG2 cells, the
sequence was homogeneously fully methylated in accord
with the data of Anwar et al. [16]. In the two urothelial
cancer tissues, differential methylation was still discer-
nible. In contrast, the urothelial cancer cell lines pre-
sented a novel methylation pattern in which CpGs 1 to 6
Figure 4 DNA methylation analysis of control regions in the 14q32 imprinted gene cluster. Bisulfite sequencing results of 11 CpGs in the
DLK1 promoter region (UCSC gene position 101192721-101192924, UCSC genome browser version 2009, Hg19), 19 CpGs in the IG DMR (UCSC
gene position 101277184-101277612) and the MEG3 DMR (UCSC gene position 101290923-101291134) in benign (left side) and tumor (right side)
samples. As benign samples, a normal kidney, leukocytes, two bladder tissues (BN) and primary cultured urothelial cells were analyzed. Tumor
samples were urothelial cancer tissues (BT), the bladder cancer cell lines SW1710 and BC61, as well as the hepatoma cell line HepG2. Black circles
indicate methylated CpGs, whereas white circles indicate unmethylated CpGs.
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17 to 19 were unmethylated, thereby resulting in a
‘striped’ pattern (Figure 4).
Distinctive DNA methylation changes were also clearly
evident in the MEG3 DMR (Figure 4, right). Benign kid-
ney, leukocytes and benign bladder tissues predominantly
harbored the typical pattern of DMRs with the expected
mixture of either fully methylated or essentially unmethy-
lated alleles (Figure 4). However, in urothelial cancer tis-
sues and cell lines, a novel pattern was observed. Again,
the methylation pattern of this region appeared striped in-
sofar as CpGs 7 to 11 tended to be densely methylated
and CpGs 1 to 4 sparsely methylated. In contrast, CpGs 5
and 6 were almost always unmethylated. Again, HepG2
cells were fully methylated, as expected.
We also analyzed several independent primary cultures
of normal urothelial cells for methylation at the three
sequences (Figure 4, [see Additional file 1: Figure S1A]).
The methylation patterns at the DLK1 promoter and the
MEG3 DMR in these cells were highly variable, tending
towards a pattern intermediate between that of normaltissue and tumors. Differential methylation at the IG
DMR appeared preserved.
Pyrosequencing analysis confirms the methylation
changes at the MEG3 differentially methylated regions in
urothelial cancer
Since the most distinctive methylation changes occurred
at the MEG3 DMR we established a pyrosequencing assay
interrogating CpGs 5 to 10 of this sequence to analyze a
larger number of samples for the presence of the novel
methylation pattern in a quantitative fashion. This assay
was applied to a larger set of benign (n = 5) and tumor
(n = 23) tissue samples, normal urothelial cells (n = 5) and
urothelial carcinoma cell lines (n = 15) (Figure 5). In ac-
cord with the bisulfite sequencing results, all analyzed
CpG positions were approximately 50% methylated in
leukocytes and benign bladder tissues (Figure 5A and B).
As predicted by bisulfite sequencing, methylation at CpG
6 was significantly decreased (P = 0.0001) in the majority
of urothelial cancer tissues and cell lines (Figure 5H),
whereas methylation at CpGs 7 to 10 was similar to
Figure 5 Pyrosequencing analysis of DNA methylation at the MEG3 differentially methylated region (DMR). Methylation of the MEG3
DMR according to quantitative bisulfite pyrosequencing in (A) 5 benign bladder tissue samples, (B) 4 leukocyte samples, (C-D) 20 urothelial
cancer tissues, (E) exceptional uniformly hypermethylated (BT58) and hypomethylated samples (cancer cell line HT1376, cancer tissues BT16,
BT28). (F, G) Average methylation of the MEG3 DMR in 5 normal urothelial cell cultures and 12 urothelial cancer cell lines. (H) Comparison of
methylation at individual CpG positions in urothelial cancer tissues (light gray) compared to benign bladder tissues (dark gray); P values were
obtained by student’s T-test. Please note that the number of lines in the graphs may appear lower than the respective ‘n’ due to overlays
between samples with very similar values.
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but was often decreased in cancer tissues and cell lines
(Figure 5C, D, G). In a few cancer tissues, methylation at
CpG 9 was exceptionally high (Figure 5C). We further-
more observed a few cancerous samples with hypomethy-
lation or hypermethylation at all analyzed CpGs compared
to benign tissues (Figure 5E), including the cancer tissue
BT152 also shown in Figures 3 and 4. For instance, the
urothelial cancer cell line HT1376 retained approximately
20% methylation across all sites. Another example is the
cancer tissue BT152, which appears to retain only a single
copy of the locus (Figure 3), which according to the pyro-
sequencing and bisulfite sequencing assay (Figure 4) is
heterogenously methylated. Cultured normal urothelial
cells tended to display increased methylation across all
CpG sites (Figure 5F), like UP124 in the bisulfite sequen-
cing analysis shown in Figure 4.These findings indicate the presence of a novel methyla-
tion pattern at the MEG3 DMR in most urothelial tumor
tissues and cell lines. In particular, reduced methylation at
CpG 6 reliably distinguishes cancerous urothelial tissues
and cell lines from the respective controls.
COBRA analysis confirms normal and tumor methylation
patterns at the DLK1 promoter
The DNA sequence in the DLK1 promoter is not well
suited for methylation analysis by pyrosequencing. There-
fore, to confirm that the consistent pattern of DNA
methylation seen in urothelial cancer tissues and cell lines
is not due to a cloning bias during bisulfite sequencing, we
designed a COBRA assay. The region contains several TaqI
restriction sites (TCGA), which are retained during bisul-
fite conversion if methylated, but mutated if unmethylated.
Thus, up to five different restriction products are obtained
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Additional file 1: Figure S2A]. Only two or three fragments
are obtained, if the sequence is consistently methylated
as suggested by the bisulfite sequencing results [see
Additional file 1: Figure S2A]. Indeed, these expected
patterns were obtained with DNA from exemplary
urothelial cancer tissues and cell lines [see Additional
file 1: Figure S2B].
Cumulatively, these findings indicate that the con-
comitant loss of DLK1 and MEG3 expression in urothe-
lial cancer is associated with the acquisition of novel
DNA methylation patterns, especially at the DLK1 pro-
moter and the MEG3 DMR that in some cases extend to
the IG DMR.
Combined treatment with Aza-dC and SAHA induces
DLK1 and MEG3 gene expression slightly
To determine to which extent DNA methylation con-
tributes to the silencing of the two genes, we tested the
effects of the DNA methyltransferase inhibitor 5-aza-2-
deoxycytidine (Aza-dC) alone or in combination with
the pan-HDAC inhibitor suberoylanilide hydroxamic acid
(SAHA) on the expression of DLK1 and MEG3 mRNA in
five urothelial cancer cell lines. Treatment with 5-aza-dC
or SAHA individually did not significantly induce MEG3
or DLK1 expression except for 5-aza-dC in the BFTC905
cell line. Combined SAHA/Aza-dC treatment consistently
restored DLK1 and MEG3 gene expression to detectable
levels [see Additional file 1: Figure S3]. However, ex-
pression was still low suggesting that silencing of the two
genes in urothelial cancer cells involves further mecha-
nisms in addition to DNA methylation.
Repressive histone modifications become strongly
enriched at DLK1-MEG3 regulatory elements in urothelial
carcinoma
Using chromatin immunoprecipitation (ChIP), we quanti-
fied the H3K4me3 histone modification associated with
active genes, the H3K9me3 and H3K27me3 modifications
associated with repression, and H4K16ac, a marker of
transcriptional competence but also of fixed nucleosomes,
at the DLK1 promoter, the IG DMR and the MEG3 DMR
in normal urothelial cells, HepG2 cells and seven urothe-
lial carcinoma cell lines (Figure 6 and [see Additional file
1: Figure S4]).
Because the variable results of DNA methylation ana-
lyses had suggested that the epigenetic state of the 14q32
region changes during culture of normal urothelial cells
(Figure 4, [see Additional file 1: Figure S1]), we used
freshly prepared, uncultured urothelial cells for the ana-
lysis of histone modifications (Figure 6). As expected for
an imprinted bivalent domain, these normal urothelial
cells displayed enrichment of H3K4me3 and H3K9me3 at
comparable levels and slightly more enriched H4K16ac atthe DLK1 promoter. The IG DMR likewise displayed
enrichment of both active and repressive histone modifi-
cations, H3K4me3 and H3K9me3, and more strongly
H3K27me3. Interestingly, H4K16ac was strongly enriched
at both DMRs. At the MEG3 DMR, in agreement with the
high expression in normal bladder, the active histone
modification H3K4me3 was enriched, whereas repressive
histone modifications (H3K9me3 and H3K27me3) were
low.
HepG2 cells were used as a DLK1 expressing control
cell line. In HepG2 cells, active and repressive histone
modifications were enriched to comparable extents at
the DLK1 promoter and the MEG3 DMR. The active
mark H3K4me3 was highly enriched at the IG DMR in
HepG2 cells, with higher levels of H3K9me3 compared
to H3K27me3, which is the inverse pattern compared to
that in normal urothelial cells.
The most striking difference in the urothelial carcinoma
cell lines towards the controls was the severe depletion
of H3K4me3 at all three regulatory regions analyzed. In
comparison, repressive histone modifications (H3K9me3
and H3K27me3) were generally increased, in particular
H3K9me3 at both DMRs, whereas increases in H3K27me3
were more evident at the DLK1 promoter and the MEG3
DMR. As a consequence, these latter two regions assumed
similar patterns of histone modifications across the uro-
thelial carcinoma cell lines. Interestingly, in contrast to the
H3K4me3 mark, the H4K14ac modification was less
severely depleted or even retained in some cell lines, with
lowered levels especially at the IG DMR.
In summary, the ChIP analyses revealed the predomin-
ance of repressive histone modifications and a nearly
complete loss of H3K4me3, with partial retention of
H4K16ac, a modification characteristic of fixed nucleo-
somes, across the entire analyzed region in all urothelial
carcinoma cells. This finding supports the contention
that the region acquires a repressive chromatin state in
urothelial carcinoma.
Discussion
Previous molecular and cytogenetic analyses of urothelial
cancers have suggested at least one tumor suppressor gene
residing at chromosome 14q32.2 [25,27,32]. This chro-
mosomal region contains a cluster of imprinted genes
important for early embryonic mammalian development.
The genes DLK1 and MEG3 within this cluster are tumor
suppressor candidates in urothelial carcinoma due to their
known functions in the regulation of cell growth and de-
velopment [20,33]. Indeed, DLK1 is downregulated by epi-
genetic mechanisms in renal cell carcinoma [5]. However,
it is upregulated in hepatocellular carcinoma cell lines and
tissues, acute myeloid leukemia and adrenocortical tu-
mors, as well as in breast, ovarian and cervical cancer cell
lines, suggesting tissue-specific functions [5,14,30,34]. The
Figure 6 (See legend on next page.)
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Figure 6 Chromatin immunoprecipitation (ChIP) analyses of histone modifications at the DLK1 promoter, the IG differentially
methylated region (DMR) and the MEG3 DMR. Results of quantitative reverse transcription polymerase chain reaction (RT-PCR) conducted
using DNA after ChIP with antibodies against active and repressive histone modifications at the DLK1 promoter (left), IG DMR (center), MEG3 DMR
(right) in HepG2 and uncultured primary urothelial cells as controls and seven urothelial carcinoma cell lines derived from tumors of different
stages and grades, that is, papillary urothelial cancer cell lines (BC61, J82, SW1710) and invasive urothelial cancer cell lines (5637, RT112, 639v
and T24). CTCFL was used as reference for a silenced gene with repressive histone marks (H3K9me3 and H3K27me3), whereas GAPDH was used as
control for a highly expressed gene with associated active histone modifications (H3K4me3 and H4K16ac). The 100% enrichment refers to the
levels at the respective control genes. An alternative representation of the Figure and additional ChIP control experiments are displayed in
Additional file 1: Figure S4.
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tumor suppressor, too, but in a more consistent manner
[1,18,19,22]. In those studies on other cancers where DNA
methylation had been investigated, homogeneous methy-
lation patterns were reported in the investigated regions
resulting from allelic loss or consistent with epitype
switching [16]. Of note, no previous study has characte-
rized the epigenetic state of the 14q32.2 cluster beyond
DNA methylation. In the present study, we used the hepa-
tocellular carcinoma line HepG2 as a control and obtained
results consistent with previous findings [5,16,30]. In ad-
ditional experiments (data not shown), we also confirmed
the reported changes in a renal carcinoma cell line [5,30].
With respect to HepG2, the homogeneous DNA methyla-
tion patterns, the copy number measurement and the sole
expression of DLK1 argue strongly that this cell line re-
tains only a paternal allele.
In previous reports on other cancer types, either DLK1
or MEG3 was reported to become deregulated, but not
both genes, as we observed in urothelial carcinoma. Un-
fortunately, many papers do not comment on whether
they have investigated the other gene at all. In benign
bladder tissues, DLK1 and MEG3 were well detectable
with MEG3 being expressed more strongly than DLK1,
like in normal kidney, liver and pituitary gland [5,30,35].
Various models for the inverse regulation of the genes in
the 14q32 imprinting cluster have been suggested [8].
Most models assume that the IG DMR activates tran-
scription of maternally expressed RNA genes such as
MEG3 and is required for silencing of the paternally
expressed genes such as DLK1. Despite their reciprocal
relationship in benign bladder tissue, MEG3 and DLK1
expression were found to be both significantly dimi-
nished in urothelial cancer tissues and cell lines. With
respect to MEG3, our findings are fully consistent with
those of Ying et al. [29]. Unfortunately, neither these
authors nor others have explicitly reported on DLK1 in
urothelial carcinoma.
Importantly, DLK1 is expressed from the paternal
allele and MEG3 from the maternal allele. Their con-
comitant downregulation is therefore difficult to explain
by allelic loss. Accordingly, we found a range of copy
numbers between one and four in urothelial carcinoma
tissues and cell lines indicating that both losses andgains of this region are frequent, accounting for the high
frequency of apparent ‘loss of heterozygosity’ in previous
reports [23,26]. However, downregulation of the two genes
was observed irrespective of whether copy numbers in-
creased, decreased or remained steady. In particular, the
copy numbers of the three sequences assayed in the region
remained identical within each sample, excluding partial
changes. Therefore, concomitant downregulation of both
DLK1 and MEG3 can indeed not be explained by chromo-
somal deletions.
By a similar argument, we can exclude conventional loss
of imprinting or epitype switching as a plausible cause of
the concomitant downregulation. If the gene cluster
assumed the maternal state, MEG3 expression should be
retained or even increased, and conversely, if the gene
cluster assumed the paternal state, DLK1 expression
should be retained or increased. Likewise, DNA methyla-
tion at the regulatory regions should become homoge-
neous and resemble either the maternal or the paternal
pattern. This type of change is exemplified by the HepG2
cell line, which shows strong DLK1 expression associated
with a paternal epigenetic state.
A clue to the actual mechanism is provided by the ob-
servation that the DNA methylation patterns at the three
regulatory regions in urothelial carcinoma cells are indeed
homogeneous, but are different from both the maternal
and paternal patterns in normal bladder and renal tissues.
These methylation patterns therefore suggest that a novel
repressed epigenetic state is established during urothelial
carcinogenesis at the 14q32 gene cluster. Of note, several
microRNAs encoded in the DLK1-MEG3 cluster (Figure 1)
within RTL1 (for example, miR127, miR136, miR431
and miR433) and between RTL1 and DIO3 (miR376a,
miR487b, miR382, miR380-5p and miR412) have also
been described to be significantly reduced or silenced by
DNA hypermethylation in bladder tumor tissues and the
cell lines RT4, RT112 and T24 [19,29] suggesting that
silencing may extend across a large part or the entire
imprinted gene cluster at 14q32. Interestingly, a co-
ordinated regional epigenetic change has been reported for
another, more centromeric, region at chromosome14q12
in urothelial carcinoma [16].
The repressed state of the DLK1-MEG3 cluster in
urothelial carcinoma cell lines is also reflected in the
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H3K9 and H3K27 trimethylation (Figure 6). Interestingly,
whereas other active modifications were lost, H4K16ac
was largely retained, despite the observation that mono-
acetylated H4K16 tends to become lost in cancer in
general [36-38]. This modification often indicates tran-
scriptional competence, but it is also associated with fixed
nucleosomes [36-38]. We speculate that the repression of
the cluster may be accompanied by rigid nucleosomal
positioning interacting with DNA methylation as docu-
mented in other cases [39]. This hypothesis is further sup-
ported by mathematical models of how DNA methylation
at CpG sites changes the physical properties, positioning
and phasing of nucleosomes [40,41]. Indeed, an overlay of
nucleosome prediction at all analyzed regulatory regions
(DLK1 promoter, MEG3 and IG DMR) with our experi-
mentally obtained methylation patterns suggest strongly
positioned and potentially newly phased nucleosomes in
cancer compared to benign urothelial cells (Additional
file 1: Figure S5). In particular, altered nucleosomal posi-
tioning could account for the peculiar patterning of DNA
methylation at the MEG3 DMR, where one specific CpG
site (#6) became significantly hypomethylated in cancer
cells, while methylation of flanking sites rather increased.
It could therefore be interesting to map the nucleosomal
positioning in the 14q imprinted gene cluster in normal
and cancer cells in future work.
Our study of the epigenetic changes at the DLK1-MEG3
cluster in urothelial carcinoma was hampered by the lack
of an epigenetically stable normal urothelial cell line. Upon
culturing, normal urothelial cells acquire a considerable
degree of plasticity, including the ability to differentiate
into epidermis-like as well as urothelial-like structures [42].
Upon immortalization by telomerase expression, further
changes ensue, in particular, deregulation of key epigenetic
regulators [43]. The DLK1-MEG3 cluster appears particu-
larly susceptible to such changes, as reduced expression or
silencing of MEG3 has also been observed in normal cell
lines originating from other tissues [35,44]. Changes in the
expression of imprinted genes, specifically of Meg3, have
also been reported during establishment of cell cultures of
mouse embryonic fibroblasts [45]. In our study, this
epigenetic instability manifested as partial changes in DNA
methylation at DLK1 and MEG3 that varied between
individual urothelial cell cultures. These changes did not
extend to the IG DMR and were not as pronounced as in
the cancer cell lines and tissues. For that reason, we used
freshly isolated, noncultured urothelial cells, which are
unfortunately only available in limited amounts, for the
chromatin immunoprecipitation experiments.
Conclusions
In conclusion, our data suggest that the 14q32 imprinted
gene cluster acquires a novel epigenetic state in urothelialcancer that allows the concomitant inactivation of DLK1
and MEG3 expression, overcoming the normally antago-
nistic regulation of these two imprinted genes. One target
of these changes is evidently MEG3, which emerges as
a tumor suppressor in many different tissues [46]. In
urothelial carcinoma, specifically, Ying et al. [29] have
demonstrated its tumor suppressor activity and our study
confirms the remarkably high frequency of its downregu-
lation reported by these authors. However, the inactivation
of MEG3 alone could be achieved by conventional mecha-
nisms such as allelic loss or by epitype switching. The
findings reported here and the observation of others that
several smaller RNA species encoded in the cluster are
downregulated by DNA hypermethylation [19,29], collect-
ively suggest that in urothelial cancers, a regional silencing
process additionally targets other genes, including poten-
tially DLK1. The question of which of these changes
support tumor progression will therefore have to be ad-
dressed by future research.Methods
Tissue samples
The bladder cancer and benign tissue samples were a
subset of those described in previous studies [2,47] com-
prising 11 benign bladder tissues (morphologically nor-
mal tissue from tumor cystectomies) and 30 bladder
cancer tissues from 25 male and 5 female patients ages
from 54 to 84 years (median age: 66 years). The tumor
stages and grades according to the current UICC classifi-
cation were as follows: pT3 G3 in 11 cases, pT4 G3 in 6
cases, pT2 G2 in 6 cases, pT2 G3 in 3 cases and one
case each of pT3 G2, pT1 G2, pTa G3 and pTa G2. The
study was approved by the ethics committee of the me-
dical faculty of the Heinrich Heine University, and all
patients gave written consent to the use of their tissues.Cell lines and cell culture
All urothelial cancer cell lines (5637, 639v, 647v, BFTC905,
HT1376, J82, RT4, RT112, SD, SW1710, Umuc3, VmCub1,
T24) and the hepatocellular carcinoma cell line HepG2
were cultured in DMEM (Gibco, Darmstadt, Germany)
supplemented with 10% fetal calf serum [48]. They were
obtained from the DSMZ (Braunschweig, Germany),
except for Umuc3 [49], kindly provided by Dr. Grossman,
Houston. The well-differentiated urothelial carcinoma cell
line BC61 derived from a papillary bladder cancer in our
lab was cultured as previously described [49,50]. Primary
urothelial cells (UP) were prepared from ureters after
nephrectomy and were routinely maintained in kera-
tinocyte serum-free medium (KSFM, Gibco, Darmstadt,
Germany) supplemented with 12.5 μg/ml bovine pituitary
extract and 0.25 ng/ml epidermal growth factor as de-
scribed [50].
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polymerase chain reaction
Total RNA was isolated from subconfluent cell cultures
and cell lines or from powdered tissues using the RNeasy
Mini or Micro Kit (Qiagen, Hilden, Germany). Two μg
RNA was reverse transcribed using 200 U SuperScriptII
reverse transcriptase (Invitrogen, Darmstadt, Germany),
with 300 ng oligo-dT and 25 ng random hexamer primers
in a reaction volume of 20 μl. Real-time PCR assays were
performed with the ABI7900HT System using the Quanti-
Tect SYBR Green PCR Kit (Qiagen, Hilden, Germany)
and QuantiTect primer assays for DLK1 and TBP in a
reaction volume of 25 μl. MEG3 primers were described
by Kawakami et al. 2006 [5]. TBP was used as a refe-
rence gene. Primers and QuantiTect assays are listed in
Additional file 1: Table S1. Statistical comparisons bet-
ween benign bladder and tumor bladder tissue expression
were made by the Mann-Whitney U Test with SPSS 21.DNA isolation and bisulfite sequencing
Total genomic DNA was isolated from subconfluent cell
cultures using the Blood and Cell Culture DNA Midi Kit
(Qiagen, Hilden, Germany). For DNA methylation ana-
lyses, 1 μg DNA was bisulfite converted using the EZ
DNA Methylation-Gold Kit (Zymo Research, Freiburg,
Germany) following the supplier’s protocol with incuba-
tions at 95°C for 10 min, followed by 64°C for 2.5 h.
After purification, the bisulfite converted DNA was ana-
lyzed for methylation of the DLK1 promoter and the
MEG3 DMR using primers described in [5] and for the
IG DMR as described in [13]. PCRs were performed in a
Biometra Thermocycler using an annealing temperature
of 55°C. The reaction mix was composed of 40 ng bisulfite
converted DNA, 150 μM dNTP, 15 pmol primer each
and 1.25 U HotStar Taq Polymerase (Qiagen, Hilden,
Germany) in the appropriate buffer. PCR products were
cloned into pCR4-TOPO. Plasmid DNA was isolated
using the Fast Plasmid Mini Kit (5Prime, Hamburg,
Germany) and several clones were sequenced using stan-
dard methods by our BMFZ core facility.DNA methylation analysis by pyrosequencing
For pyrosequencing analysis of the MEG3 DMR bisulfite-
treated DNA samples were used with newly designed
primers [see Additional file 1: Table S1] using the fol-
lowing conditions: initial denaturation step at 95°C for
15 min, followed by 42 cycles consisting of denaturation
at 95°C for 20 s, annealing at 57°C and extension at 72°C
for 30 s. Pyrosequencing was carried out on a PyroMark
Q24 instrument (Qiagen) according to the manufacturer's
instruction. This pyrosequencing analysis interrogated the
CpG positions 5 to 10 in the MEG3 DMR region analyzed
by standard bisulfite sequencing.Gene copy number analysis
For gene copy number analysis by qPCR 25 ng total
genomic DNA was used with the QuantiTect SYBR
Green PCR Kit (Qiagen, Hilden, Germany) and primers
for DLK1, IG DMR and MEG3 DMR as in ChIP analysis
[see Additional file 1: Table S1]. PCR conditions were as
follows: 95°C for 15 min, followed by 30 cycles of
94°C for 15 s, annealing (55 to 60°C) for 30 s, 72°C for
10 to 14 s. GAPDH was used as a reference gene. Gene
copy numbers were calculated as the ratio of the mea-
sured sequence to the reference gene GAPDH and nor-
malized to the value from leukocyte DNA set as two
copies.Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
on triplicate samples with the ChIP-IT Express Kit
(Active Motif, Rixensart, Belgium) according to the
manufacturer’s instructions as previously described
[51] or 105 primary urothelial cells freshly prepared
from a ureter after nephrectomy using the True Micro-
ChIP kit (Diagenode, Liege, Belgium). The precipitated
DNA fractions were quantified by real-time PCR with
the QuantiTect SYBR Green PCR Kit (Qiagen, Hilden,
Germany) and primers for the DLK1 promoter, IG
DMR and MEG3 DMR. ChIP assays [see Additional
file 1: Table S1] were located in the regions analyzed
for DNA methylation. PCR conditions were as follows:
95°C for 15 min, followed by 45 cycles of 94°C for 15 s,
annealing (55 to 60°C) for 30 s, 72°C for 30 s. Isotype
(IgG) control values were subtracted. CTCFL was used
as a control for a silenced gene with inactive histone
modifications (H3K9me3 and H3K27me3), whereas
GAPDH was used as control for a highly expressed
gene with active histone modifications (H3K4me3,
H4K14ac). The input DNA purified from the sheared
unprecipitated chromatin was used to make a standard
curve for each gene investigated and each sample was
measured in duplicate with less than 12% variation.
The 100% enrichment refers to the levels at the re-
spective control genes. The results remained in prin-
ciple unchanged, if the values were normalized to input
DNA directly (compare Figure 6 and [Additional file 1:
Figure S4A]). Also, the enrichment of the H3K27me3
modification compared to the H3K4me3 modification
at the DLK1 promoter, IG DMR and MEG3 DMR of
UC cell lines remained clearly evident when, in an in-
dependently performed experiment, the values were
normalized to input DNA as well as immunoprecipi-
tated total H3 [Additional file 1: Figure S4B]. The fol-
lowing antibodies were used: anti-H3K4me3, anti-
H3K27me3 (Abcam, Cambridge, UK), anti-H3K27me3,
anti-H4K16Ac, anti-H3 (Active motif, La Hulpe, Belgium).
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